Resonance Health signs UK CRO deal to expand clinical trials services
Resonance Health (ASX:RHT) entered a strategic alliance and master services agreement with UK CRO Image Analysis to include software as a medical device (SaMD) services in global clinical trials, with the initial deal lasting 24 months and targeting high-growth indications such as obesity and metabolic disease.